Skip to content

CRISPR Therapeutics CRSP Income Statement

FY'25FY'24FY'23FY'22
$3.51M-90.6%$37.31M-89.9%$371.21M+30,885%$1.2M-99.9%
$284.81M-8.2%$310.24M-19.9%$387.33M-16.1%$461.65M+36.0%
$73.54M+0.8%$72.98M-4.2%$76.16M-25.7%$102.46M+1.7%
$668.08M+32.6%$503.88M-15.1%$593.74M-12.0%$674.36M+24.6%
-$664.57M-42.4%-$466.57M-$673.16M
-18,933.6%-17,683pp-1,250.4%-56,190.4%
$86.61M-16.6%$103.9M+44.7%$71.82M+217%$22.66M+277%
-$577.97M-59.4%-$362.67M-$650.5M
$3.63M+1.3%$3.59M+24.2%$2.89M+989%-$325K
-$581.6M-58.8%-$366.25M-$650.18M
-16,569.8%-15,588pp-981.5%-54,271.7%
-$6.50-49.4%-$4.35-$8.36
-$645.09M-44.2%-$447.31M-$648.99M
-18,378.7%-17,180pp-1,198.8%-54,172.7%
-$664.57M-42.4%-$466.57M-$673.16M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does CRISPR Therapeutics's income statement data come from?
Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.